ST
NKTR icon

Spot Trading’s Nektar Therapeutics NKTR Stock Holding History

Spot Trading’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$636K Buy
1,767
+1,147
+185% +$359K 0.01% 1473
2017
Q2 		$182K Buy
620
+593
+2,196% +$171K ﹤0.01% 2281
2017
Q1 		$9K Buy
+27
New +$6.07K ﹤0.01% 2759
2016
Q3 		– Sell
-460
Closed -$98K – 3368
2016
Q2 		$98K Buy
+460
New +$103K ﹤0.01% 2535
2016
Q1 		– Sell
-5,400
Closed -$1.36M – 3790
2015
Q4 		$1.36M Buy
+5,400
New +$1.11M 0.01% 1251

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Spot Trading's NKTR Position: Q3 2017 in Review

Spot Trading reduced its Nektar Therapeutics (NKTR) stake by 38% in Q3 2017, selling an estimated $78.5K and leaving 402 shares worth $145K. The position accounts for ﹤0.01% of the portfolio, ranked #2401.

Spot Trading first reported a position in NKTR in Q2 2014 and has held it in 5 quarters since. The position peaked at $192K in Q2 2017. 203 funds tracked by Wall St. Rank hold NKTR as of Q3 2017.

  • Spot Trading held 402 shares of Nektar Therapeutics worth $145K as of Q3 2017.
  • Spot Trading sold 251 Nektar Therapeutics shares in Q3 2017, an estimated $78.5K.
  • Nektar Therapeutics made up ﹤0.01% of Spot Trading's portfolio in Q3 2017, its #2401 holding.
  • Spot Trading first reported a position in Nektar Therapeutics in Q2 2014 and has held it in 5 quarters since.
  • Spot Trading's Nektar Therapeutics position peaked at $192K in Q2 2017.
  • 203 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2017.

Based on Spot Trading's 13F filing for Q3 2017, filed 6 Nov 2017.